A 12-month double-blind, double-dummy, randomised, parallel-group, multicenter efficacy and safety study of Symbicort® pMDI 2x160/4.5 µg bid and 2x80/4.5 µg bid compared to formoterol TBH 2x4.5 µg bid and placebo in patients with COPD